These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 8620506)

  • 1. Changes in cellular components of spleen and lymph node cells and the effector cells responsible for Meth A tumor eradication induced by zinostatin stimalamer.
    Masuda E; Maeda H
    Cancer Res; 1996 Apr; 56(8):1868-73. PubMed ID: 8620506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor resistance induced by zinostatin stimalamer (ZSS), a polymer-conjugated neocarzinostatin (NCS) derivative. I. Meth A tumor eradication and tumor-neutralizing activity in mice pretreated with ZSS or NCS.
    Masuda E; Maeda H
    Cancer Immunol Immunother; 1995 May; 40(5):329-38. PubMed ID: 7600566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in cellular composition induced by neocarzinostatin pretreatment in Meth A-bearing mice and the responsible antitumor effector cells.
    Masuda E; Shishido T; Fujimoto R; Maeda H
    Immunopharmacology; 1997 Aug; 37(1):105-16. PubMed ID: 9285249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulatory role of T lymphocytes and NK cells in tumor allograft development.
    Sobotková E; Nouza K
    Neoplasma; 1993; 40(2):75-80. PubMed ID: 8350958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antitumor effects of a new antitumor agent, zinostatin stimalamer (YM881)--effects on experimental tumors in vitro and in vivo].
    Numasaki Y; Takahashi K; Masuda E; Nohara C; Maeda H
    Gan To Kagaku Ryoho; 1991 Oct; 18(13):2289-94. PubMed ID: 1834021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
    Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
    J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Importance of Lyt-2+ T-cells in the resistance of melphalan-cured MOPC-315 tumor bearers to a challenge with MOPC-315 tumor cells.
    Barker E; Mokyr MB
    Cancer Res; 1988 Sep; 48(17):4834-42. PubMed ID: 3261626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity of orally administered SMANCS, a polymer-conjugated protein drug, in mice bearing various murine tumors.
    Schmitt DA; Kisanuki K; Kimura S; Oka K; Pollard RB; Maeda H; Suzuki F
    Anticancer Res; 1992; 12(6B):2219-24. PubMed ID: 1295469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin 18 induces the sequential activation of natural killer cells and cytotoxic T lymphocytes to protect syngeneic mice from transplantation with Meth A sarcoma.
    Micallef MJ; Tanimoto T; Kohno K; Ikeda M; Kurimoto M
    Cancer Res; 1997 Oct; 57(20):4557-63. PubMed ID: 9377569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of natural killer cells and macrophages in the nonspecific resistance to tumors in mice stimulated with SMANCS, a polymer-conjugated derivative of neocarzinostatin.
    Suzuki F; Pollard RB; Uchimura S; Munakata T; Maeda H
    Cancer Res; 1990 Jul; 50(13):3897-904. PubMed ID: 2141295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Activation and regulation of macrophages induced by inoculation of cryodestroyed tumor cells].
    Tsujino M
    Osaka Daigaku Shigaku Zasshi; 1990 Jun; 35(1):180-205. PubMed ID: 2135404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Augmentation of in vitro interleukin 10 production after in vivo administration of interleukin 18 is activated macrophage-dependent and is probably not involved in the antitumor effects of interleukin 18.
    Micallef MJ; Tanimoto T; Kohno K; Ikeda M; Ikegami H; Kurimoto M
    Anticancer Res; 1998; 18(6A):4267-74. PubMed ID: 9891477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection and characterization of anti-tumour effector cells in Meth-A-bearing mice treated with recombinant human interleukin 2.
    Naruo KI; Hinuma S; Shiho O; Houkan T; Ootsu K; Tsukamoto K
    Clin Exp Immunol; 1989 May; 76(2):278-83. PubMed ID: 2788049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An increase in mouse tumor growth by an in vivo immunomodulating effect of titanium dioxide nanoparticles.
    Moon EY; Yi GH; Kang JS; Lim JS; Kim HM; Pyo S
    J Immunotoxicol; 2011; 8(1):56-67. PubMed ID: 21288165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response of T and B lymphocytes in the spleen, lymph nodes and mammary tumors in rats treated with human soluble tumor-associated antigens and commercial human albumin.
    Ben-Hur H; Kossoy G; Mehrdad H; Elhayany A; Zusman I
    Oncol Rep; 2004 Dec; 12(6):1329-33. PubMed ID: 15547759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of astaxanthin and its mode of action.
    Jyonouchi H; Sun S; Iijima K; Gross MD
    Nutr Cancer; 2000; 36(1):59-65. PubMed ID: 10798217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Anticancer effects of OK-432 (2). Anticancer actions of M phi activated by OK-432].
    Saito M; Aonuma E; Noda T; Nakadate I; Nanjo M; Ebina T; Ishida N
    Gan To Kagaku Ryoho; 1983 May; 10(5):1363-71. PubMed ID: 6870302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies on the mechanisms of action of the immunomodulator Bestatin in various screening test systems.
    Schorlemmer HU; Bosslet K; Dickneite G; Lüben G; Sedlacek HH
    Behring Inst Mitt; 1984 May; (74):157-73. PubMed ID: 6383322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of the potentiation of specific antitumor immunity by intratumor injection of Corynebacterium parvum.
    Miyata H; Himeno K; Nomoto K
    Cancer Res; 1983 Oct; 43(10):4670-5. PubMed ID: 6883325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytotoxic T-cell-mediated antitumor effect of levamisole against murine syngeneic fibrosarcoma.
    Gomi K; Morimoto M; Nomoto K
    Cancer Res; 1982 Oct; 42(10):4197-202. PubMed ID: 6980702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.